Copyright: ©Author(s) 2026.
World J Gastroenterol. Dec 14, 2026; 32(46): 121840
Published online Dec 14, 2026. doi: 10.3748/wjg.121840
Published online Dec 14, 2026. doi: 10.3748/wjg.121840
Figure 1 Cost-effectiveness frontier for all strategies (100000 cohort members).
The plotted points represent all 600 evaluated strategies. Strategies positioned on the cost-effectiveness frontier dominate those located to their upper left, respectively, and their names and incremental cost-effectiveness ratios compared to the next most effective non-dominated strategy are presented. Costs and quality-adjusted life-years are expressed as the value in 2024. US: Ultrasound; AFP: Alpha fetoprotein; QALY: Quality-adjusted life-year; Gd-MRI: Gadoxetic-enhanced magnetic resonance imaging.
- Citation: Zhang YB, Li YX, Zhang WD, Hou XB, Li R, Xia RY, Shen MW, Zou ZR, Zhuang GH. Cost-effectiveness of risk-stratified hepatocellular carcinoma screening using the age-male-albumin-bilirubin-platelets score-based stepwise enrichment approach in patients with cirrhosis. World J Gastroenterol 2026; 32(46): 121840
- URL: https://www.wjgnet.com/1007-9327/full/v32/i46/121840.htm
- DOI: https://dx.doi.org/10.3748/wjg.121840